Financial Highlights - Adjusted EBITDA for Q4 2023 was $115.4 million[6] - Adjusted Free Cash Flow for Q4 2023 was $18.6 million[6] - The company spent $7.4 million on share repurchases, repurchasing 1.8 million shares[6] - Denny's domestic system-wide same-restaurant sales increased by 1.3% versus 2022[6] Sales Performance - Denny's Q4 2023 domestic average weekly sales outperformed Q4 2022 by 3.2%[10] - Off-premise sales are more popular with younger generations and diverse guests[14] - The Burger Den is active in over 1,200 domestic locations, and The Meltdown is in over 1,100 domestic locations[16] Footprint and Franchise - Denny's has a total of 1,407 restaurants in the U S[20] - Denny's international footprint includes 166 restaurants in 14 countries and U S territories, grown by approximately 91% since year end 2010[23] - The company has a strong partnership with 208 franchisees operating 1,508 franchisee restaurants[27]

2015 Fourth Quarter Earnings Conference Call February 25, 2016 1 Greg Panagos Vice President of Investor Relations 2 Susan Story President and Chief Executive Officer Walter Lynch Chief Operating Officer Forward-Looking Statements Certain statements in this presentation including, without limitation, 2015 earnings guidance, the outcome of pending acquisition activity, the amount of future capital investments, and estimated revenues from rate cases and other government agency authorizations, are forward-look ...

Pipeline and Milestones - Centessa Pharmaceuticals 专注于发现和开发针对患者的变革性药物[7, 50]。 - 公司预计在 2025 年实现 OX2R 激动剂管线的多个临床里程碑[7, 50]。 - ORX750 的 2a 期临床数据预计在 2025 年公布，针对嗜睡症 I 型 (NT1)、嗜睡症 II 型 (NT2) 和特发性嗜睡症 (IH) 患者[10]。 - ORX142 在急性睡眠剥夺的健康志愿者中的临床数据预计在 2025 年公布[10]。 - ORX489 正在推进 IND (新药研究申请) 支持性研究[10, 49]。 ORX750 and Market Opportunity - ORX750 是一种高效、选择性的 OX2R 激动剂，有潜力重新定义睡眠-觉醒障碍患者的标准治疗方法[21]。 - NT1、NT2 和 IH 代表着庞大的潜在患者群体，美国约有 62 万名患者[23, 25]。 - 在美国，大约有 27 万名 NT1、NT2 和 IH 患者被诊断和治疗[23, 25]。 ORX750 Clinical Data - 在一项研究中，2.5 毫克、3.5 毫克和 5.0 毫克剂量的 ORX750 在急性睡眠剥夺的健康志愿者中均产生了超过 30 分钟的 MWT LS 平均睡眠潜伏期[29]。 - ORX750 在 KSS 评分中显示出剂量依赖性的显著改善，与安慰剂相比，剂量 ≥ 2.5 毫克时具有显著性[32]。 - ORX750 显示出良好的安全性和耐受性[38]。

Company Overview - Zevra Therapeutics is focused on bringing life-changing therapeutics to the rare disease community[9] - The company has two commercial-stage rare disease products and an advanced clinical development pipeline[8,82] - Zevra has a strong financial position with $217 million in cash, cash equivalents, and investments as of April 1, 2025, including $687 million as of March 31, 2025, plus $1483 million net proceeds from a PRV sale[8,81] Product Portfolio - MIPLYFFA (arimoclomol) is FDA-approved for Niemann-Pick Disease Type C (NPC) and launched in November 2024[20] - Approximately 900 individuals in the U S live with NPC, with 300-350 diagnosed or treated[38] - OLPRUVA (sodium phenylbutyrate) for oral suspension is FDA-approved for Urea Cycle Disorders (UCD) in patients weighing 20 kg or greater and with a body surface area (BSA) of 12 m2 or greater[20,50] - Approximately 1,100 individuals are diagnosed with UCDs in the U S [59] Pipeline Development - The company is targeting an EMA MAA submission for arimoclomol in Europe in the second half of 2025[49] - Celiprolol is in Phase 3 development for Vascular Ehlers-Danlos Syndrome (VEDS), with IP through 2038[20] - Approximately 7,500 individuals in the U S are diagnosed with VEDS[74]

Becker Muscular Dystrophy (BMD) - Sevasemten shows positive observations in Becker patients with continued dosing[12] - A positive Type C FDA meeting offers a clear path to potential approval for Sevasemten[12] - The GRAND CANYON trial is on track for topline data in Q4 2026[12], with >98% power to deliver a statistically significant difference in NSAA vs placebo[20] - In the CANYON study, the NSAA score between the Sevasemten group and the placebo group showed a difference of +1.12 at month 12[27] - In the MESA open-label study, 99% of eligible participants are currently enrolled[30] - Natural history modeling reveals that 92% of CANYON participants improved vs their predicted scores[39], and 89% of ARCH participants achieved higher NSAA scores vs predicted[42] Duchenne Muscular Dystrophy (DMD) - In the LYNX & FOX trials, Sevasemten treatment reduced the functional decline in Duchenne patients[15] - A path to Phase 3 is open with the selection of 10 mg as the target dose[16] - In Duchenne patients, a -82% change in TNNI2 was observed in the 30mg cohort at Month 3[72] - In the FOX study, participants are an average of 11 years old and 4 years out from receiving gene therapy[99] Financial Status - Edgewise has approximately $624 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing a cash runway through 2028[112][113]

Financial Performance - American Water's adjusted earnings per share (EPS) from continuing operations increased from $2.64 in 2015 to $2.84 in 2016[29] - The company affirms its 2017 guidance range for EPS to be $2.98 - $3.08[79] - The company anticipates a 7-10% EPS Compound Annual Growth Rate (CAGR) through 2021, anchored off 2015 EPS[34] - The company's common dividends declared showed a CAGR of 10% from 2014 to 2017[35] - American Water's capital investment reached a record level of $1.3 billion in 2016 for regulated infrastructure[24] - Cash flow from operations increased by 8.2% from 2015 to 2016[77] Regulated Business - The company's regulated business remains the foundation of its long-term growth strategy[23] - The Illinois Commerce Commission approved a $35.2 million rate increase for American Water, authorizing a 9.79% Return on Equity (ROE)[41] - The company closed acquisitions serving approximately 42,000 customers and had pending acquisitions for approximately 40,000 customers in 2016[24] - The company's O&M efficiency ratio improved to 34.9% in 2016 and is targeting 32.5% by 2021[24, 50]

2017 Fourth Quarter and Year-End Earnings Conference Call NYSE: AWK NYSE: AWK Forward-Looking Statements Ed Vallejo Vice President, Investor Relations NYSE: AWK NYSE: AWK www.amwater.com 2 Forward-Looking Statements Certain statements in this presentation including, without limitation, 2018 earnings guidance, projected long-term earnings and dividend growth, our projected operation & maintenance efficiency ratio, the outcome of pending acquisition activity and estimated revenues from rate cases and other go ...

Solana Treasury Strategy - Upexi expands into crypto, focusing exclusively on Solana, with a treasury valued at $121 million as of May 28 [6] - The company raised $100 million in a private placement to bootstrap its Solana treasury strategy [6, 27] - Upexi estimates $7 million in annual staking revenue from staked SOL [6] - Upexi purchased $44 million of discounted locked SOL [6] - The company's treasury consists of 679,677 SOL, with 58% locked and 42% spot [38] Capital Markets & Valuation - Upexi leverages capital markets strategies, including a recent $100 million private placement, to maximize value [18, 20] - The company targets additional large-scale, accretive capital raises to acquire more Solana [21, 27] - Upexi aims to issue equity in an accretive fashion and is considering convertible debt at attractive terms [22] - Staking yields are consistently 7-9%, and buying discounted locked SOL effectively doubles the staking yield [28, 38] Solana & Crypto Thesis - Solana is positioned as a leading blockchain with ultra-cheap transactions and a bustling ecosystem [17] - The company believes Solana has high upside potential, with a market cap only 4% of Bitcoin's [28, 51]

Financial Highlights - Noble Corporation's market capitalization is $6.2 billion[6] - The company's 2023 Free Cash Flow (FCF) was $184 million[6] - The company's 2023 Adjusted EBITDA was $810 million[6] - The company's backlog stands at $4.6 billion[6] - The company's quarterly dividend is $0.40[6] - The company's 2023 Adjusted EBITDA margin was 31%[6] Market Overview - Average deepwater greenfield investment is expected to increase by 60% in 2025-27 compared to 2021-24[9] - Tier-1 Ultra-Deepwater (UDW) marketed utilization is at 100%[14] - Total UDW marketed utilization is at 97%[14] - Total floater marketed utilization is at 95%[14]

Company Strategy & R&D Model - BeOne aims to transform cancer care globally by delivering innovative medicines faster, more equitably, and affordably[12, 16] - The company's R&D model leverages a prolific research organization, global manufacturing, efficient clinical development, and global commercial access to achieve superior R&D returns[25] - BeOne focuses on delivering high-quality innovation by designing superior molecules with exceptional profiles and halting programs that don't meet high standards; over 60 preclinical programs have been terminated in the past 3.5 years[30, 32] - The company is building a deep pipeline, aiming to deliver 8-10 highly differentiated new molecular entities (NMEs) into the clinic in each focused disease area in the next 3-6 years[42] Hematology Portfolio & CLL - BeOne is positioned to address unmet needs in CLL with a wholly-owned portfolio including BRUKINSA, sonrotoclax, and BTK CDAC[93] - BRUKINSA is the only BTKi to demonstrate PFS superiority over ibrutinib in a head-to-head Phase 3 R/R CLL trial[100] - In treatment-naive CLL/SLL patients, 60-month PFS with zanubrutinib was 72.2% in patients with del(17p), similar to 75.8% in patients without del(17p)[105] - Sonrotoclax + zanubrutinib achieved fast and deep responses in TN CLL/SLL, with 84% uMRD at week 48 in the 160mg dose group and 92% uMRD in the 320mg dose group[133] Solid Tumor Portfolio - The global CDK4/6i market is large and growing, estimated at approximately $13 billion[244] - BG-C9074 (B7-H4 ADC) demonstrated a confirmed ORR of 24% and an unconfirmed ORR of 29% among 68 efficacy-evaluable patients, with activity at 6mg/kg Q3W showing a confirmed ORR of 43% and an unconfirmed ORR of 48%[296] - BGB-58067 (PRMT5i) showed early responses at the second dose level in a Phase 1 study, with three objective responses observed in histologically distinct tumor types[331]